October 4, 2024/
No Comments
Immuron (NASDAQ: IMRN), plans IND submission for CDI treatment in 2025 Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical…
Immuron (NASDAQ: IMRN), plans IND submission for CDI treatment in 2025 Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical…
Immuron (NASDAQ: IMRN), plans IND submission for CDI treatment in 2025 Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical…
Retail Investor Support
Equity Research Coverage
Public Relations